Prognostic significance of the mitochondrial scoring system in ovarian cancer

Matsumoto,Ryuma; Isonishi,Seiji; Ochiai,Kazuhiko; Hamada,Tomomi; Kiyokawa,Takako; Tachibana,Toshiaki; Ishikawa,Hiroshi

doi:10.3892/etm.2010.118

Prognostic significance of the mitochondrial scoring system in ovarian cancer

Authors:
- Ryuma Matsumoto
- Seiji Isonishi
- Kazuhiko Ochiai
- Tomomi Hamada
- Takako Kiyokawa
- Toshiaki Tachibana
- Hiroshi Ishikawa
View Affiliations

Affiliations: Department of Obstetrics/Gynecology, Jikei University Daisan Hospital, Tokyo 201-8601, Japan, Department of Pathology, Jikei University Daisan Hospital, Tokyo 201-8601, Japan, Department of Anatomy, Jikei University Daisan Hospital, Tokyo 201-8601, Japan
Published online on: July 20, 2010 https://doi.org/10.3892/etm.2010.118
Pages: 783-788

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We report a mitochondrial (MT) scoring system related to response to platinum treatment in ovarian cancer (OC). Ultra-thin sections of surgical specimens of primary tumors prepared from 41 OC patients were examined by electron microscopy. The ovarian carcinoma cell line 2008 and its platinum-resistant variant C13 were used as controls. Seven independent MT features, including MT diameter, pattern of cresta structure, electron density, MT distribution, pattern of distribution, ovoid ratio and MT architecture, were examined. Each of the seven parameters was assigned a point score of 0-2 and was summed up with a total score of 14. Clinical response and in vitro sensitivity to platinum, taxane, irinotecan and doxorubicin were evaluated. Clinical information was available for 37 of the 41 cases. Twenty-four cases were stage III and, histologically, 16 serous, 6 endometrioid and 6 clear cell carcinoma were included. All of the patients underwent surgery followed by 6 cycles of taxane and platinum chemotherapy. Fifteen patients exhibited a response, while 22 were resistant to treatment. The total MT score was 5.13±1.13 (mean ± SE) in the 15 responsive cases and 11.41±0.43 in the 22 resistant cases (P<0.001). Receptor operative characteristic (ROC) analysis revealed that the resistant total ‘cut-off’ score was ≥10 points (P<0.05; AUC=0.86) with 95.5% sensitivity and 80.0% specificity. The MT scoring system correlated well with response to drugs, with the exception of doxorubicin. The progression-free survival (PFS) curves showed an absolute difference in the 6-month PFS of 10% (83 vs. 73%) and in the 12-month PFS of 21% (80 vs. 59%), in favor of patients with low MT scores. This MT scoring system correlates very closely with clinical response as well as cellular sensitivity to chemotherapy, resulting in an association with PFS.

View Figures

View References

1.	Armstrong D, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J and Burger R; for the Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K and Noda K; for the Japanese Gynecologic Oncology Group: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer; a phase III, open-label, randomized controlled trial. Lancet. 374:1331–1338. 2009. View Article : Google Scholar
3.	Saitou M, Isonishi S, Hamada T, Kiyokawa T, Tachibana T, Ishikawa H and Yasuda M: Mitochondrial ultrastructure associated chemotherapy response in ovarian cancer. Oncol Rep. 21:199–204. 2008.PubMed/NCBI
4.	Hirama M, Isonishi S, Yasuda M and Ishikawa H: Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells. Oncol Rep. 16:997–1002. 2006.PubMed/NCBI
5.	Isonishi S, Saitou M, Ochiai K, Yasuda M and Tanaka T: Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells. Gynecol Oncol. 90:413–420. 2003. View Article : Google Scholar
6.	Kim TS, Yun BY and Kim IY: Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. Biochem Pharmacol. 66:2301–2311. 2003. View Article : Google Scholar
7.	Chilin A, Dodoni G, Frezza C, Guiotto A, Barbieri V, Di Lisa F and Canton M: 4-Hydroxymethyl-1,6,8-trimethylfuro [2,3-h] quinolin-2(1H)-one induces mitochondrial dysfunction and apoptosis upon its intracellular oxidation. J Med Chem. 48:192–199. 2005.
8.	Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO and Scambia G: Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol. 64:51–58. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC and Clarke R: Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem. 282:5934–5943. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Flatters SJ and Bennett GJ: Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 122:245–257. 2006. View Article : Google Scholar
11.	Liu L, Vo A, Liu G and McKeehan WL: Distinct structural domains within C19ORF5 support association with stabilized microtubules and mitochondrial aggregation and genome destruction. Cancer Res. 65:4191–4201. 2005. View Article : Google Scholar
12.	André N, Carré M, Brasseur G, Pourroy B, Kovacic H, Briand C and Braguer D: Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 532:256–260. 2002.PubMed/NCBI
13.	Matassa AA, Carpenter L, Biden TJ, Humphries MJ and Reyland ME: PKC delta is required for mitochondrial-dependent apoptosis in salivary epithelial cells. J Biol Chem. 276:29719–29728. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Grivicich I, Regner A, da Rocha AB, Grass LB, Alves PA, Kayser GB, Schwartsmann G and Henriques JA: Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines. Oncol Res. 5:385–392. 2005.
15.	Silverberg SG: Histopathologic grading of ovarian carcinoma: a review and proposal. Intl J Gynecol Pathol. 19:7–15. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, Munsell MF, Gaertner E, Frishberg D and Silva EG: Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 31:1168–1174. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM and Silva EG: Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 28:496–504. 2004. View Article : Google Scholar : PubMed/NCBI
18.	Mc Cluggage WG, Lyness RW, Atkinson RJ, Dobbs SP, Harley I, Mc Clelland HR and Price JH: Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol. 55:27–31. 2002.
19.	Benda JA and Zaino R: GOG Pathology Manual. Gynecologic Oncology Group; Buffalo, NY: 1994
20.	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
21.	Rustin GJ: Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 21:S187–S193. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Ishikawa T, Zhu BL and Maeda H: Effects of therapeutic agents on cellular respiration as an indication of metabolic activity. Hum Exp Toxicol. 25:135–140. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Amano Y, Okumura C, Yoshida M, Katayama H, Unten S, Arai J, Tagawa T, Hoshina S and Ishikawa H: Measuring respiration of cultured cell with oxygen electrode as a metabolic indicator for drug screening. Human Cell. 12:3–10. 1999.PubMed/NCBI
24.	Disaida PJ, Sinkovics JG, Rutledge FN and Smith JP: Cell-mediated immunity to human malignant cells. Am J Obstet Gynecol. 114:979–989. 1972.PubMed/NCBI
25.	Andrews PA, Murphy MP and Howell SB: Differential potentiation of alkylating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 45:6250–6253. 1985.
26.	Parmar MKB and Machin D: Survival Analysis: A Practical Approach. John Wiley & Sons Inc.; New York: pp. 160–177. 1995
27.	Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C and Bruckner HW: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay. Clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 55:5276–5282. 1995.
28.	Brown E and Markman M: Tumor chemosensitivity and chemoresistance assays. Cancer. 72:1020–1025. 1996. View Article : Google Scholar
29.	Tate Thigpen J: Debate; therapy for a patient with platinum-resistant/refractory recurrent ovarian cancer should be selected based on results of an in vitro drug sensitivity/resistance assay. Clin Ovarian Cancer. 1:96–110. 2008.
30.	Markman M, Blessing JA, DeGeest K, Morgan M, Look KY, Herzog TJ and Rose PG: Lack of efficacy of 24-hour infusional topotecan in platinum-refractory ovarian cancer; a Gynecologic Oncology Group trial. Gynecol Oncol. 75:444–446. 1999. View Article : Google Scholar : PubMed/NCBI
31.	Brewer C, Blessing J, Nagourney R, Morgan M and Hanjani P: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer; a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 103:446–450. 2006. View Article : Google Scholar : PubMed/NCBI
32.	Markman M, Blessing J, Rubin SC, Connor J, Hanjani P and Waggoner S: Phase II trial of weekly paclitaxel (80 mg/m²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers; a Gynecologic Oncology Group study. Gynecol Oncol. 101:436–440. 2006.PubMed/NCBI